Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome

被引:80
作者
Guo, LM
Liu, JY
Xu, DZ
Li, BS
Han, H
Wang, LH
Zhang, WY
Lu, LH
Guo, X
Sun, FX
Zhang, HY
Liu, XD
Zhang, JP
Yao, Y
He, ZP
Wang, MM
机构
[1] Beijing DiTan Hosp, ICU & Artificial Liver Support Ctr, Beijing, Peoples R China
[2] Beijing DiTan Hosp, Virol Lab, Beijing, Peoples R China
[3] Univ Rostock, Therapeut Blood Purificat Res Ctr, Rostock, Germany
关键词
liver failure; artificial liver support; MARS; MODS; NO; cytokine;
D O I
10.1034/j.1478-3231.23.s.3.7.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Molecular Adsorbents Recirculating System (MARS) is a new promising artificial liver support therapy, the aim of this study was to assess the effectiveness of MARS to remove nitrous oxide (NO) and cytokines in severe liver failure patients with multiple organ dysfunction syndrome (MODS). Methods: Sixty single MARS treatments were performed with length of 6-24 h on 24 severe liver failure patients (18 males/6 females) with MODS. Results: The MARS therapy was associated with a significant removal of NO and certain cytokines such as TNF-alpha, IL-6, IL-8, and INF-gamma, together with marked reduction of other non-water-soluble albumin bound toxins and water-soluble toxins, these were associated with a improvement of the patients' clinical conditions including hepatic encephalopathy, deranged hemodynamic situation and as well as renal and respiratory function, thus resulted into marked decrease of Sequential Organ Failure Assessment (SOFA) score and improved outcome: nine patients were able to be discharged from the hospital or bridged to successful liver transplantation, the overall survival of 24 patients was 37.5%. Conclusion: We can confirm the positive therapeutic impact and safety to use MARS on liver failure patients with MODS associated with elevated levels of NO and cytokines.
引用
收藏
页码:16 / 20
页数:5
相关论文
共 12 条
[1]   Can the clearance of tumor necrosis factor alpha and interleukin 6 Be enhanced using an albumin dialysate hemodiafiltration system [J].
Awad, SS ;
Sawada, S ;
Soldes, OS ;
Rich, PB ;
Klein, R ;
Alarcon, WH ;
Wang, SC ;
Bartlett, RH .
ASAIO JOURNAL, 1999, 45 (01) :47-49
[2]   Artificial hepatic support - Where are we now? [J].
Davenport, A .
BLOOD PURIFICATION, 2001, 19 (01) :1-3
[3]   Intestinal endotoxemia as a pathogenetic mechanism in liver failure [J].
Han, DW .
WORLD JOURNAL OF GASTROENTEROLOGY, 2002, 8 (06) :961-965
[4]   Infections and the inflammatory response in acute respiratory distress syndrome [J].
Headley, AS ;
Tolley, E ;
Meduri, GU .
CHEST, 1997, 111 (05) :1306-1321
[5]  
HIRASAWA H, 1999, THER APHER, V3, P4
[6]   Acute-on-chronic liver failure: Pathophysiological basis of therapeutic options [J].
Jalan, R ;
Williams, R .
BLOOD PURIFICATION, 2002, 20 (03) :252-261
[7]  
Mitzner SR, 2001, J AM SOC NEPHROL, V12, pS75
[8]   Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure [J].
Schmidt, LE ;
Sorensen, VR ;
Svendsen, LB ;
Hansen, BA ;
Larsen, FS .
LIVER TRANSPLANTATION, 2001, 7 (12) :1034-1039
[9]   Cytokines, for better or worse? [J].
Simpson, KJ .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (09) :957-966
[10]  
SORKINE P, 2001, 2001 YB INTENSIVE CA, P619